The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
19 | 7 | 29 | 25 |
Growth
|
89 | 55 | 61 | 83 |
Safety
|
42 | 40 | 74 | 17 |
Sentiment
|
50 | 21 | 20 | 10 |
|
48 | 8 | 37 | 11 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
62 | 55 | 77 | 5 |
Opinions Change
|
63 | 50 | 50 | 50 |
Pro Holdings
|
n/a | 15 | 1 | 82 |
Market Pulse
|
21 | 22 | 13 | 7 |
Sentiment
|
50 | 21 | 20 | 10 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
19 | 7 | 29 | 25 |
Growth
|
89 | 55 | 61 | 83 |
|
42 | 40 | 74 | 17 |
Combined
|
49 | 8 | 67 | 31 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
7 | 1 | 11 | 11 |
Price vs. Earnings (P/E)
|
9 | 15 | 7 | 1 |
Price vs. Book (P/B)
|
78 | 60 | 68 | 100 |
Dividend Yield
|
1 | 1 | 1 | 1 |
Value
|
19 | 7 | 29 | 25 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
4 | 100 | 96 | 94 |
Profit Growth
|
96 | 26 | 4 | 72 |
Capital Growth
|
94 | 9 | 99 | 95 |
Stock Returns
|
97 | 65 | 31 | 3 |
Growth
|
89 | 55 | 61 | 83 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
47 | 50 | 100 | 1 |
Refinancing
|
94 | 78 | 94 | 94 |
Liquidity
|
1 | 1 | 1 | 1 |
|
42 | 40 | 74 | 17 |
Discover high‑ranked alternatives to Theravance Biopharma and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.